| Indication | Global Market Size |
Pre Clinical |
Phase Ib |
Phase IIb |
Support for EU Conditional Marketing Approval Submission |
Post EU Marketing US Phase 3 |
|
|---|---|---|---|---|---|---|---|
| Organ failure associated with Sepsis | $33B | Completed | Phase II Initiated Q1 2021 |
Completion of Phase II Q4 2022 |
|||
| ARDS associated with severe/critical COVID-19 | $1B (COVID) | Completed COVID-19 |
Phase II Completed COVID-19 |
Completion of Phase IIb Q4 2023/Q1 2023 |
|||
| Solid tumors in combination with chemotherapy, immune checkpoints | $4B | Phase Ib Q1 2022 |
|||||
Pipelinemonimono2021-11-21T14:10:03+02:00
